BRIEF-Tianjin Development Posts FY Total Revenue From Ops For Tianjin Lisheng Pharmaceutical RMB1.39 Bln

Reuters03-10

BRIEF-Tianjin Development Posts FY Total Revenue From Ops For <a href="https://laohu8.com/S/002393">Tianjin Lisheng</a> Pharmaceutical RMB1.39 Bln

March 10 (Reuters) - Tianjin Lisheng Pharmaceutical Co Ltd 002393.SZ:

FY TOTAL REVENUE FROM OPERATIONS FOR TIANJIN LISHENG PHARMACEUTICAL RMB1.39 BILLION
FY PRELIM NET PROFIT AFTER EXTRAORDINARY ITEMS ATTRIBUTABLE FOR TIANJIN LISHENG PHARMACEUTICAL RMB169.1 MILLION

Further company coverage: 002393.SZ

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618062696?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 08:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618062696","market":"nz","top_or_hot":-1,"title":"BRIEF-Tianjin Development Posts FY Total Revenue From Ops For Tianjin Lisheng Pharmaceutical RMB1.39 Bln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Tianjin Development Posts FY Total Revenue From Ops For <a href=\"https://laohu8.com/S/002393\">Tianjin Lisheng</a> Pharmaceutical RMB1.39 Bln</title></head><body><p><span>March 10 (Reuters)</span><span> - </span>Tianjin Lisheng Pharmaceutical Co Ltd <span>002393.SZ</span>:</p><ul><li><p>FY TOTAL REVENUE FROM OPERATIONS FOR TIANJIN LISHENG PHARMACEUTICAL RMB1.39 BILLION</p></li><li><p>FY PRELIM NET PROFIT AFTER EXTRAORDINARY ITEMS ATTRIBUTABLE FOR  TIANJIN LISHENG PHARMACEUTICAL RMB169.1 MILLION</p></li></ul><p>Further company coverage: <span>002393.SZ</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Tianjin Development Posts FY Total Revenue From Ops For Tianjin Lisheng Pharmaceutical RMB1.39 Bln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Tianjin Development Posts FY Total Revenue From Ops For Tianjin Lisheng Pharmaceutical RMB1.39 Bln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-10 08:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Tianjin Development Posts FY Total Revenue From Ops For <a href=\"https://laohu8.com/S/002393\">Tianjin Lisheng</a> Pharmaceutical RMB1.39 Bln</title></head><body><p><span>March 10 (Reuters)</span><span> - </span>Tianjin Lisheng Pharmaceutical Co Ltd <span>002393.SZ</span>:</p><ul><li><p>FY TOTAL REVENUE FROM OPERATIONS FOR TIANJIN LISHENG PHARMACEUTICAL RMB1.39 BILLION</p></li><li><p>FY PRELIM NET PROFIT AFTER EXTRAORDINARY ITEMS ATTRIBUTABLE FOR  TIANJIN LISHENG PHARMACEUTICAL RMB169.1 MILLION</p></li></ul><p>Further company coverage: <span>002393.SZ</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0188","symbol_name":"融资融券","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nFWN3ZX0WL:1","article_id":"2618062696","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618062696","pubTimestamp":1773104053,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Tianjin Development Posts FY Total Revenue From Ops For Tianjin Lisheng Pharmaceutical RMB1.39 BlnMarch 10  - Tianjin Lisheng Pharmaceutical Co Ltd 002393.SZ:FY TOTAL REVENUE FROM OPERATIONS FOR TIANJIN LISHENG PHARMACEUTICAL RMB1.39 BILLIONFY PRELIM NET PROFIT AFTER EXTRAORDINARY ITEMS ATTRIBUTABLE FOR  TIANJIN LISHENG PHARMACEUTICAL RMB169.1 MILLIONFurther company coverage: 002393.SZ ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0188":"融资融券","00882":"天津发展","002393":"力生制药","BK0028":"国家队","BK0239":"医药制造","BK1232":"复合型公用事业"},"translate_title":"简介-天津发展公布天津力生制药财年Ops总收入为人民币13.9亿元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00882":0.9,"002393":0.9},"content_text":"BRIEF-Tianjin Development Posts FY Total Revenue From Ops For Tianjin Lisheng Pharmaceutical RMB1.39 BlnMarch 10 (Reuters) - Tianjin Lisheng Pharmaceutical Co Ltd 002393.SZ:FY TOTAL REVENUE FROM OPERATIONS FOR TIANJIN LISHENG PHARMACEUTICAL RMB1.39 BILLIONFY PRELIM NET PROFIT AFTER EXTRAORDINARY ITEMS ATTRIBUTABLE FOR  TIANJIN LISHENG PHARMACEUTICAL RMB169.1 MILLIONFurther company coverage: 002393.SZ ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport,express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618062696","isCrawlerRequest":true}